Impact of antivirals and emergence of drug resistance: HSV-2 epidemic control

H. B. Gershengorn, S. M. Blower

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Genital herpes, caused by herpes simplex virus type-2 (HSV-2), affects more people worldwide than any other sexually transmitted disease (STD). Antivirals are effective in decreasing the duration of symptoms and in reducing viral shedding; however, currently antiviral usage is extremely low. Increased usage of antivirals would have a beneficial epidemic-level effect (due to the decreased transmission of drug-sensitive strains) as well as potentially a detrimental epidemic-level effect (if drug-resistant strains emerge and are transmitted). Previously, we have developed a mathematical model that we have used to predict (with a degree of uncertainty) the beneficial and the potential detrimental epidemic-level effects of increased antiviral usage. Here, we use our model to make further predictions about the impact of increasing antiviral usage. We calculate the effect, on individual patients, of antiviral usage in terms of: (1) the decrease in the average number of infectious days per year and (2) an individual's lifetime probability of acquiring permanent drug resistance. We also use our model: (1) to determine the probability of eliminating herpes by antivirals and (2) to quantify the effect of increasing antiviral usage on decreasing HSV-2 prevalence. Our results show that theoretically it would be possible to eliminate herpes epidemics by using a drug that does not cure.

Original languageEnglish (US)
Pages (from-to)133-142
Number of pages10
JournalAIDS Patient Care and STDs
Volume14
Issue number3
DOIs
StatePublished - 2000
Externally publishedYes

Fingerprint

Viral Drug Resistance
Human Herpesvirus 2
Antiviral Agents
Pharmaceutical Preparations
Virus Shedding
Herpes Genitalis
Sexually Transmitted Diseases
Drug Resistance
Uncertainty
Theoretical Models

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Leadership and Management
  • Nursing(all)

Cite this

Impact of antivirals and emergence of drug resistance : HSV-2 epidemic control. / Gershengorn, H. B.; Blower, S. M.

In: AIDS Patient Care and STDs, Vol. 14, No. 3, 2000, p. 133-142.

Research output: Contribution to journalArticle

Gershengorn, H. B. ; Blower, S. M. / Impact of antivirals and emergence of drug resistance : HSV-2 epidemic control. In: AIDS Patient Care and STDs. 2000 ; Vol. 14, No. 3. pp. 133-142.
@article{a971a523dfdc48e68ab11c34a2add85c,
title = "Impact of antivirals and emergence of drug resistance: HSV-2 epidemic control",
abstract = "Genital herpes, caused by herpes simplex virus type-2 (HSV-2), affects more people worldwide than any other sexually transmitted disease (STD). Antivirals are effective in decreasing the duration of symptoms and in reducing viral shedding; however, currently antiviral usage is extremely low. Increased usage of antivirals would have a beneficial epidemic-level effect (due to the decreased transmission of drug-sensitive strains) as well as potentially a detrimental epidemic-level effect (if drug-resistant strains emerge and are transmitted). Previously, we have developed a mathematical model that we have used to predict (with a degree of uncertainty) the beneficial and the potential detrimental epidemic-level effects of increased antiviral usage. Here, we use our model to make further predictions about the impact of increasing antiviral usage. We calculate the effect, on individual patients, of antiviral usage in terms of: (1) the decrease in the average number of infectious days per year and (2) an individual's lifetime probability of acquiring permanent drug resistance. We also use our model: (1) to determine the probability of eliminating herpes by antivirals and (2) to quantify the effect of increasing antiviral usage on decreasing HSV-2 prevalence. Our results show that theoretically it would be possible to eliminate herpes epidemics by using a drug that does not cure.",
author = "Gershengorn, {H. B.} and Blower, {S. M.}",
year = "2000",
doi = "10.1089/108729100317911",
language = "English (US)",
volume = "14",
pages = "133--142",
journal = "AIDS Patient Care and STDs",
issn = "1087-2914",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Impact of antivirals and emergence of drug resistance

T2 - HSV-2 epidemic control

AU - Gershengorn, H. B.

AU - Blower, S. M.

PY - 2000

Y1 - 2000

N2 - Genital herpes, caused by herpes simplex virus type-2 (HSV-2), affects more people worldwide than any other sexually transmitted disease (STD). Antivirals are effective in decreasing the duration of symptoms and in reducing viral shedding; however, currently antiviral usage is extremely low. Increased usage of antivirals would have a beneficial epidemic-level effect (due to the decreased transmission of drug-sensitive strains) as well as potentially a detrimental epidemic-level effect (if drug-resistant strains emerge and are transmitted). Previously, we have developed a mathematical model that we have used to predict (with a degree of uncertainty) the beneficial and the potential detrimental epidemic-level effects of increased antiviral usage. Here, we use our model to make further predictions about the impact of increasing antiviral usage. We calculate the effect, on individual patients, of antiviral usage in terms of: (1) the decrease in the average number of infectious days per year and (2) an individual's lifetime probability of acquiring permanent drug resistance. We also use our model: (1) to determine the probability of eliminating herpes by antivirals and (2) to quantify the effect of increasing antiviral usage on decreasing HSV-2 prevalence. Our results show that theoretically it would be possible to eliminate herpes epidemics by using a drug that does not cure.

AB - Genital herpes, caused by herpes simplex virus type-2 (HSV-2), affects more people worldwide than any other sexually transmitted disease (STD). Antivirals are effective in decreasing the duration of symptoms and in reducing viral shedding; however, currently antiviral usage is extremely low. Increased usage of antivirals would have a beneficial epidemic-level effect (due to the decreased transmission of drug-sensitive strains) as well as potentially a detrimental epidemic-level effect (if drug-resistant strains emerge and are transmitted). Previously, we have developed a mathematical model that we have used to predict (with a degree of uncertainty) the beneficial and the potential detrimental epidemic-level effects of increased antiviral usage. Here, we use our model to make further predictions about the impact of increasing antiviral usage. We calculate the effect, on individual patients, of antiviral usage in terms of: (1) the decrease in the average number of infectious days per year and (2) an individual's lifetime probability of acquiring permanent drug resistance. We also use our model: (1) to determine the probability of eliminating herpes by antivirals and (2) to quantify the effect of increasing antiviral usage on decreasing HSV-2 prevalence. Our results show that theoretically it would be possible to eliminate herpes epidemics by using a drug that does not cure.

UR - http://www.scopus.com/inward/record.url?scp=0034029866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034029866&partnerID=8YFLogxK

U2 - 10.1089/108729100317911

DO - 10.1089/108729100317911

M3 - Article

C2 - 10763542

AN - SCOPUS:0034029866

VL - 14

SP - 133

EP - 142

JO - AIDS Patient Care and STDs

JF - AIDS Patient Care and STDs

SN - 1087-2914

IS - 3

ER -